Raymond James Financial Inc. Invests $2.43 Million in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Raymond James Financial Inc. purchased a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 84,883 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,432,000. Raymond James Financial Inc. owned approximately 0.26% of Collegium Pharmaceutical at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Barclays PLC increased its holdings in Collegium Pharmaceutical by 152.2% in the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock worth $2,899,000 after buying an additional 45,291 shares during the last quarter. Franklin Resources Inc. increased its holdings in Collegium Pharmaceutical by 13.4% in the third quarter. Franklin Resources Inc. now owns 30,625 shares of the specialty pharmaceutical company’s stock worth $1,164,000 after buying an additional 3,620 shares during the last quarter. Principal Financial Group Inc. increased its holdings in Collegium Pharmaceutical by 3.9% in the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after buying an additional 64,958 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Collegium Pharmaceutical by 173.6% in the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after buying an additional 175,892 shares during the last quarter. Finally, Harbor Capital Advisors Inc. increased its holdings in Collegium Pharmaceutical by 15.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 27,150 shares of the specialty pharmaceutical company’s stock worth $778,000 after buying an additional 3,652 shares during the last quarter.

Wall Street Analysts Forecast Growth

COLL has been the subject of several research reports. Piper Sandler reduced their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. Needham & Company LLC reissued a “buy” rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. HC Wainwright reissued a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Finally, StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 19th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $43.60.

Insider Buying and Selling

In related news, CFO Colleen Tupper sold 977 shares of the firm’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the transaction, the chief financial officer now owns 164,269 shares of the company’s stock, valued at approximately $4,928,070. This trade represents a 0.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Scott Dreyer sold 2,255 shares of the firm’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the transaction, the executive vice president now directly owns 124,421 shares of the company’s stock, valued at approximately $3,732,630. This trade represents a 1.78 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 81,693 shares of company stock worth $2,334,994 over the last ninety days. Company insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Price Performance

Collegium Pharmaceutical stock opened at $27.60 on Wednesday. The firm has a market capitalization of $886.84 million, a P/E ratio of 11.90 and a beta of 0.76. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $42.29. The business has a 50-day moving average of $28.30 and a 200-day moving average of $30.60. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.09. The company had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. On average, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.